- Home
- VERV vs SPXX Comparison
VERV vs SPXX Comparison
Compare VERV & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERV
- SPXX
- Stock Information
- Founded
- VERV 2018
- SPXX 2004
- Country
- VERV United States
- SPXX United States
- Employees
- VERV N/A
- SPXX N/A
- Industry
- VERV Medicinal Chemicals and Botanical Products
- SPXX Trusts Except Educational Religious and Charitable
- Sector
- VERV Health Care
- SPXX Finance
- Exchange
- VERV Nasdaq
- SPXX Nasdaq
- Market Cap
- VERV 384.2M
- SPXX 313.6M
- IPO Year
- VERV 2021
- SPXX N/A
- Fundamental
- Price
- VERV $11.06
- SPXX $16.94
- Analyst Decision
- VERV Buy
- SPXX
- Analyst Count
- VERV 9
- SPXX 0
- Target Price
- VERV $14.75
- SPXX N/A
- AVG Volume (30 Days)
- VERV 7.8M
- SPXX 51.3K
- Earning Date
- VERV 08-07-2025
- SPXX 01-01-0001
- Dividend Yield
- VERV N/A
- SPXX 7.55%
- EPS Growth
- VERV N/A
- SPXX N/A
- EPS
- VERV N/A
- SPXX N/A
- Revenue
- VERV $59,613,000.00
- SPXX N/A
- Revenue This Year
- VERV $27.75
- SPXX N/A
- Revenue Next Year
- VERV N/A
- SPXX N/A
- P/E Ratio
- VERV N/A
- SPXX N/A
- Revenue Growth
- VERV 271.44
- SPXX N/A
- 52 Week Low
- VERV $2.87
- SPXX $13.57
- 52 Week High
- VERV $11.41
- SPXX $16.05
- Technical
- Relative Strength Index (RSI)
- VERV 84.74
- SPXX 43.09
- Support Level
- VERV $5.88
- SPXX $16.85
- Resistance Level
- VERV $11.41
- SPXX $17.12
- Average True Range (ATR)
- VERV 0.49
- SPXX 0.18
- MACD
- VERV 0.64
- SPXX -0.08
- Stochastic Oscillator
- VERV 95.00
- SPXX 11.39
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on approximately 35%-75% of the notional value of the Fund's equity portfolio in an effort to enhance the Fund's risk-adjusted returns.